BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3000668)

  • 1. Ovarian cancer: histogenetic classification, histologic grading, diagnosis, staging, and epidemiology.
    Jolles CJ
    Clin Obstet Gynecol; 1985 Dec; 28(4):787-99. PubMed ID: 3000668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
    Young RH
    Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
    Ulbright TM
    Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adjuvant therapy of malignant ovarian tumors after organ preserving surgery].
    Schröder W
    Zentralbl Gynakol; 1996; 118(10):565-70. PubMed ID: 8912476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological classification and grading of primary ovarian carcinoma: experience of the ARTAC ovarian study group.
    Vacher-Lavenu MC; Le Tourneau A; Duvillard P; Godefroy N; Pinel MC
    Bull Cancer; 1993 Feb; 80(2):135-41. PubMed ID: 8173164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
    Veras E; Deavers MT; Silva EG; Malpica A
    Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
    Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
    Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma.
    Sorbe B; Frankendal B; Veress B
    Obstet Gynecol; 1982 May; 59(5):576-82. PubMed ID: 7070728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histologic type and tumor maturity as prognostic factors in malignant epithelial tumors of the ovary].
    Jukić S; Ilić J; Krstulović B; Krznar B; Culig V
    Jugosl Ginekol Perinatol; 1989; 29(3-4):137-9. PubMed ID: 2601368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the management of epithelial ovarian cancer.
    Berkenblit A; Cannistra SA
    J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer.
    Barber HR; Sommers SC; Synder R; Kwon TH
    Am J Obstet Gynecol; 1975 Mar; 121(6):795-807. PubMed ID: 1092171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Histologic classification and morphologic prognostic factors in malignant ovarian tumors].
    Horn LC; Fricke K; Krugmann J
    Zentralbl Gynakol; 1995; 117(7):335-45. PubMed ID: 7668062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current issues in the pathology of ovarian cancer.
    Rabban JT; Bell DA
    J Reprod Med; 2005 Jun; 50(6):467-74. PubMed ID: 16050571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival.
    Diefenbach CS; Soslow RA; Iasonos A; Linkov I; Hedvat C; Bonham L; Singer J; Barakat RR; Aghajanian C; Dupont J
    Cancer; 2006 Oct; 107(7):1511-9. PubMed ID: 16944535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.